60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Sees Significant Growth in Short Interest

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 130,700 shares, a growth of 95.1% from the March 31st total of 67,000 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average daily trading volume, of 335,700 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, April 3rd.

60 Degrees Pharmaceuticals Price Performance

60 Degrees Pharmaceuticals stock remained flat at $0.24 during midday trading on Friday. 94,376 shares of the company’s stock were exchanged, compared to its average volume of 94,055. The stock has a fifty day moving average price of $0.27 and a two-hundred day moving average price of $0.55. 60 Degrees Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $8.65.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.44) EPS for the quarter. The business had revenue of ($0.10) million for the quarter, compared to the consensus estimate of $0.06 million. Research analysts expect that 60 Degrees Pharmaceuticals will post -0.29 earnings per share for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.